The KIFFIK team combines decades of experience across healthcare, medical devices, diagnostics, and commercialization. We are united by a shared commitment to advancing access to interstitial fluid and enabling new approaches to biological measurement and monitoring.
“With first-of-its-kind technology, you need a team with demonstrated leadership and proven success across the business spectrum. The team we've built at KIFFIK collectively has more than 200 years of experience and is a proven collective of excellence."
Chief Executive Officer
Chief Operating Officer
Chief Commercial Officer
Chief Business Officer
Chief Medical Officer
Chief Scientific Officer
Chief Technology Officer
Chief Financial Officer
Chief Legal Officer
President, EMEA
President, Animal Health
EVP, Corporate Development
EVP, Product Development
EVP, Marketing
EVP, IP & Licensing
EVP, Operations
General Manager
Chief Legal Officer
Chief Executive Officer
Chief Operating Officer
EVP, Operations
Chief Medical Officer
King's College London, Professor, Pharmaceutical Innovation.
Royal Pharmaceutical Society, Chief Scientist.
Royal Pharmaceutical Society, Chief Scientist.
University of Birmingham, Professor of Cancer Genetics and Surgery.
Birmingham CRUK Experimental Cancer Medicine Centre, Deputy Director.
Birmingham CRUK Experimental Cancer Medicine Centre, Deputy Director.
NIHR Leeds Musculoskeletal Biomedical Research Centre: Head of Scleroderma Programme.
Susan Cheney Professor of Experimental Medicine.
Susan Cheney Professor of Experimental Medicine.
Professor of Internal Medicine, VCU School of Medicine; Associate Director for Global Oncology, VCU Massey Comprehensive Cancer Center; Member of the Developmental Therapeutics Research Program, VCU Massey Comprehensive Cancer Center
Professor of Internal Medicine, VCU School of Medicine; Associate Director for Global Oncology, VCU Massey Comprehensive Cancer Center; Member of the Developmental Therapeutics Research Program, VCU Massey Comprehensive Cancer Center
KIFFIK collaborates with organizations across healthcare, diagnostics, beauty, animal health, and research to advance the development and application of interstitial fluid technologies.
Duracell is collaborating with KIFFIK to evaluate advanced power solutions for future biomonitoring and wearable technologies, supporting long-term device performance, continuous monitoring, and next-generation biological measurement.
Beacon MedTech Solutions is supporting device engineering, manufacturing, and Design for Manufacturing (DFM) activities across the K-EXP platform, helping accelerate the transition from clinical deployment in 2026 to scalable commercial production in 2027.
HekaBio is supporting KIFFIK's expansion across Japan and Asia-Pacific, helping establish regulatory pathways, clinical collaborations, and strategic commercial partnerships throughout the region.
KIFFIK welcomes opportunities to collaborate with organizations interested in exploring, advancing, and applying interstitial fluid technologies across diagnostics, monitoring, drug development, beauty, animal health,
and biological research.
